Benlysta
(belimumab)GlaxoSmithKline LLC
Usage: BENLYSTA (belimumab) is indicated for patients aged 5 and older with active systemic lupus erythematosus and active lupus nephritis, both receiving standard therapy. Its efficacy in severe active central nervous system lupus is not evaluated, hence it is not recommended for such cases.